Versant Venture Capital VI, L.P.
CIK 1687880 · last filed 2025-08-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$48.35M
Companies
7
Total Filings
27
Lifetime Open-Market Net
-$98.34M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | 10%+ Owner | 2,299,292 | $5.88 | $13.52M | -$216.73M | 3 | 2025-08-26 |
| IPSC | 10%+ Owner | 13,259,905 | $2.05 | $27.18M | $0 | 1 | 2021-12-28 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | 10%+ Owner | 2,319,446 | $22.26 | $51.63M | $18.36M | 1 | 2021-07-01 |
| BDTX | 10%+ Owner | 4,343,210 | $1.76 | $7.64M | $39.27M | 9 | 2020-11-25 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 3,754,051 | $60.05 | $225.43M | $0 | 1 | 2020-07-21 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 7,297,318 | $54.65 | $398.80M | -$24.20M | 8 | 2020-07-10 |
| Oyster Point Pharma, Inc. (OYST) Delisted | 10%+ Owner | 2,945,158 | $11.17 | $32.90M | $84.96M | 1 | 2019-11-04 |
Recent Filings · Page 2 of 3
27 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-13 | BDTX | Mixed | −3,862,392 | -$2.13M | EDGAR |
| 2020-10-28 | BDTX | Sell (S) | −35,612 | -$1.19M | EDGAR |
| 2020-10-20 | BDTX | Sell (S) | −62,984 | -$2.11M | EDGAR |
| 2020-10-08 | BDTX | Mixed | −1,342,136 | -$6.14M | EDGAR |
| 2020-09-21 | BDTX | Other (J) | −2,916,864 | $0 | EDGAR |
| 2020-08-20 | BDTX | Other (J) | −1,200,000 | $0 | EDGAR |
| 2020-07-21 | Pandion Therapeutics, Inc. (PAND) Delisted | Conv (C) | +22,524,306 | $0 | EDGAR |
| 2020-07-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −159,171 | -$3.18M | EDGAR |
| 2020-07-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | −2,269,761 | -$4.28M | EDGAR |
| 2020-02-05 | BDTX | Mixed | +42,211,572 | $68.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.